{"classes":[{"categories":[{"measurements":[{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"4"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"14"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"7"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"5"},{"groupId":"OG022","value":"2"},{"groupId":"OG023","value":"6"},{"groupId":"OG024","value":"3"},{"groupId":"OG025","value":"3"}]}],"title":"ADA-negative at baseline"},{"categories":[{"measurements":[{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"2"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"2"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"1"},{"groupId":"OG024","value":"1"},{"groupId":"OG025","value":"0"}]}],"title":"ADA-positive at post-baseline (i.e. ADA incidence)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"5"},{"groupId":"OG016","value":"16"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"7"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"5"},{"groupId":"OG022","value":"2"},{"groupId":"OG023","value":"6"},{"groupId":"OG024","value":"4"},{"groupId":"OG025","value":"3"}],"units":"Participants"}],"description":"Validated immunoassays were used for screening and confirmation of the presence of anti-PDR001 antibodies (ADA, anti-drug antibodies) in serum. Number of participants with ADA in each category is reported in this record.","groups":[{"description":"Single-agent LAG525 1 mg/kg Q2W","id":"OG000","title":"Phase 1: LAG525 1 mg/kg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q2W","id":"OG001","title":"Phase 1: LAG525 3 mg/kg Q2W"},{"description":"Single-agent LAG525 5 mg/kg Q2W","id":"OG002","title":"Phase 1: LAG525 5 mg/kg Q2W"},{"description":"Single-agent LAG525 10 mg/kg Q2W","id":"OG003","title":"Phase 1: LAG525 10 mg/kg Q2W"},{"description":"Single-agent LAG525 15 mg/kg Q2W","id":"OG004","title":"Phase 1: LAG525 15 mg/kg Q2W"},{"description":"Single-agent LAG525 240 mg Q2W","id":"OG005","title":"Phase 1: LAG525 240 mg Q2W"},{"description":"Single-agent LAG525 400 mg Q2W","id":"OG006","title":"Phase 1: LAG525 400 mg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q4W","id":"OG007","title":"Phase 1: LAG525 3 mg/kg Q4W"},{"description":"Single-agent LAG525 5 mg/kg Q4W","id":"OG008","title":"Phase 1: LAG525 5 mg/kg Q4W"},{"description":"Single-agent LAG525 10 mg/kg Q4W","id":"OG009","title":"Phase 1: LAG525 10 mg/kg Q4W"},{"description":"Single-agent LAG525 400 mg Q4W","id":"OG010","title":"Phase 1: LAG525 400 mg Q4W"},{"description":"Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG011","title":"Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG012","title":"Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)","id":"OG013","title":"Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG014","title":"Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG015","title":"Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG016","title":"Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG017","title":"Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG018","title":"Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)","id":"OG019","title":"Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG020","title":"Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG021","title":"Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG022","title":"Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG023","title":"Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG024","title":"Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG025","title":"Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients in phase 1 who received at least one full or partial dose of PDR001 and who had a determinant baseline immunogenicity (IG) sample and at least one determinant post-baseline IG sample. A determinant IG sample is neither ADA-inconclusive nor unevaluable.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).","title":"Phase 1: Number of Participants With Anti-PDR001 Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}